5-Amino-1MQ is a small-molecule research compound used to investigate nicotinamide N-methyltransferase biochemistry in purified-enzyme assays, cultured cells, and institutionally approved laboratory animal models.
This article does not provide instructions for human or veterinary use, administration, dosing, self-experimentation, or personal application.
5-Amino-1MQ commonly refers to 5-amino-1-methylquinolinium, a synthetic quinolinium compound developed as an inhibitor of nicotinamide N-methyltransferase, abbreviated NNMT.
It is a synthetic research small molecule. It is not a peptide, a GLP-1 analogue such as semaglutide, a hormone fragment such as AOD9604, a protein, an amino-acid polymer, or an approved medicine.

It has no amino-acid sequence. Its identity is defined by its aromatic cationic structure and by the counterion present in the supplied salt form.
The most commonly referenced research form is 5-amino-1-methylquinolinium iodide. PubChem records this iodide salt with the molecular formula C10H11IN2, a molecular weight of approximately 286.11 g/mol, and CAS Registry Number 42464-96-0.[1]
The corresponding 5-amino-1-methylquinolinium cation has the molecular formula C10H11N2+, a molecular weight of approximately 159.21 g/mol, and CAS Registry Number 685079-15-6.[2] The parent-cation and salt relationship is also represented in the U.S. Food and Drug Administration Global Substance Registration System.[3]
The cation and its iodide salt must not be treated as having the same molecular weight in quantitative calculations. Every experiment should use the exact salt form, formula weight, hydration or solvation state, assay value, and identity information stated on the batch-specific certificate of analysis.
As of the review date, 5-Amino-1MQ is not an FDA-approved drug. In a January 20, 2026 warning letter, FDA specifically identified 5-amino-1-methylquinolinium iodide as a bulk substance that did not qualify for the cited section 503B compounding exemptions because it was not on the 503B bulks list and was not being used to compound a drug on the shortage list.[4] This article does not support marketing or use of 5-Amino-1MQ as a drug, dietary supplement, or other consumer product.
The research interest in 5-Amino-1MQ arises from its ability to inhibit NNMT, an intracellular enzyme that transfers a methyl group from S-adenosyl-L-methionine to nicotinamide. This reaction intersects with nicotinamide metabolism, NAD+ salvage, methyl-donor balance, 1-methylnicotinamide production, and broader cellular metabolic regulation.
Appropriate interpretation: 5-Amino-1MQ is an NNMT-focused chemical probe supported primarily by biochemical, cellular, and preclinical animal evidence. It is not a general-purpose metabolic product and should not be represented as having established human efficacy or safety.
Molecular Identity and Material Form
Core chemical information
| Parameter | Research information |
|---|---|
| Common research name | 5-Amino-1MQ |
| Parent cation | 5-Amino-1-methylquinolinium |
| Common supplied salt | 5-Amino-1-methylquinolinium iodide |
| Iodide-salt formula | C10H11IN2 |
| Iodide-salt molecular weight | Approximately 286.11 g/mol |
| Iodide-salt CAS number | 42464-96-0 |
| Parent-cation formula | C10H11N2+ |
| Parent-cation molecular weight | Approximately 159.21 g/mol |
| Parent-cation CAS number | 685079-15-6 |
| Compound class | Quinolinium small molecule |
| Peptide status | Not a peptide; no amino-acid sequence |
| Primary research target | Nicotinamide N-methyltransferase |
A calculation based on 159.21 g/mol cannot be applied to a bottle containing the iodide salt with a formula weight of approximately 286.11 g/mol. Hydrates, solvates, alternative counterions, or non-stoichiometric water content can introduce additional differences.
Researchers should record, at minimum:
- the complete chemical name;
- the stated salt or counterion;
- the formula weight shown on the COA;
- the assigned purity and, where available, assay or content value;
- the lot number;
- the storage requirements;
- the date received and date first opened;
- the solvent system used;
- the preparation date and storage history of each research solution.
Purity, identity, and assay are different quality attributes
HPLC purity, mass-spectrometric identity, and absolute assay answer different analytical questions.
A chromatographic purity result estimates the relative amount of material represented by the main chromatographic component under a defined method. It does not, by itself, establish molecular identity, counterion content, water content, residual-solvent profile, elemental composition, or absolute mass balance.
Mass spectrometry can support identity confirmation by detecting an expected ion or fragmentation pattern. A matching ion alone does not establish chromatographic purity or prove that all other batch quality attributes are acceptable.
Where pharmaceutical-development or regulated analytical expectations are relevant, ICH Q2(R2) may be used as a reference for analytical-procedure validation. The extent of validation for a research-use-only material should be defined according to the intended analytical purpose and applicable quality system.
Relevant characteristics may include specificity, accuracy, precision, linearity, range, and robustness where applicable.[5]
A research-material COA may therefore report separate results for:
- identity testing;
- HPLC or UPLC purity;
- assay or content;
- water content;
- counterion or salt content;
- residual solvents;
- appearance;
- solubility testing;
- elemental composition or other batch-relevant tests.
Residual solvents are a separate impurity category and should be evaluated according to the manufacturing process and analytical purpose. ICH Q3C(R8) may serve as a risk-based reference when pharmaceutical-development standards are applicable; it should not be presented as automatically mandatory for every RUO reagent.
An HPLC area percentage must not be presented as proof that residual solvents are absent.[6]
A specification such as “≥98% by HPLC” may be appropriate for a particular research project, but it is not a universal guarantee of identity, biological suitability, sterility, safety, or performance in every assay.
NNMT Biochemistry and Catalytic Mechanism
NNMT is a cytosolic methyltransferase that catalyzes the following reaction:
Nicotinamide + S-adenosyl-L-methionine → 1-methylnicotinamide + S-adenosyl-L-homocysteine
- nicotinamide is abbreviated NAM;
- S-adenosyl-L-methionine is abbreviated SAM;
- 1-methylnicotinamide is abbreviated 1-MNA or MNAM;
- S-adenosyl-L-homocysteine is abbreviated SAH.
Kinetic analysis of human NNMT supports a rapid-equilibrium ordered mechanism in which SAM binds before nicotinamide. After methyl transfer, the methylated nicotinamide product and SAH are released.[7]
This ordered mechanism matters when interpreting inhibitor potency because measured activity can vary with SAM concentration, NAM concentration, enzyme concentration, incubation duration, temperature, buffer composition, product accumulation, and detection technology.
An IC50 value measured under one set of purified-enzyme conditions is not a universal constant and is not equivalent to a cellular working concentration. In intact cells, apparent activity can be affected by membrane transport, intracellular accumulation, chemical stability, protein binding, cell density, nutrient conditions, endogenous NAM and SAM concentrations, and NNMT expression.
Biochemical and cellular potency
5-Amino-1MQ was developed as a substrate-site-directed NNMT inhibitor based on a quinolinium scaffold. Under specified recombinant-enzyme assay conditions, published work reported an NNMT IC50 of approximately 1.2 µM.[8]
In fully differentiated 3T3-L1 adipocytes, 24-hour treatment produced concentration-dependent suppression of intracellular 1-MNA with a fitted cellular EC50 of approximately 2.3 ± 1.1 µM and a reported goodness-of-fit R2 of 0.94.[8]
This cellular estimate should be interpreted cautiously. The published dose-response curve used only two replicates per concentration point.
It is therefore best treated as an exploratory estimate under that specific 3T3-L1 protocol, not as a universally validated cellular potency value.
The biochemical IC50 and cellular EC50 describe different experimental systems:
- the biochemical IC50 describes inhibition in a controlled enzyme assay;
- the cellular EC50 describes a measured intracellular response in a defined cell model;
- neither establishes a universal concentration for every cell line, exposure duration, or laboratory protocol.
The same study tested 5-Amino-1MQ against a limited panel of other methyltransferases and NAD-related enzymes and reported preferential NNMT inhibition under the tested conditions.[8] A targeted panel is not equivalent to complete proteome-wide, transporter-wide, ion-channel, receptor, or metabolome-wide selectivity profiling.
Cellular findings are therefore strengthened by proximal target-engagement evidence, such as reduced 1-MNA formation, and where practical by orthogonal methods such as genetic NNMT manipulation, direct binding or occupancy evidence, or a structurally distinct NNMT inhibitor.
The NNMT–NAM–NAD+ Axis
Competition for intracellular nicotinamide
Nicotinamide is generated by several NAD+-consuming processes and can be returned to NAD+ through the salvage pathway. Nicotinamide phosphoribosyltransferase converts NAM to nicotinamide mononucleotide, after which nicotinamide mononucleotide adenylyltransferases produce NAD+.
NNMT creates a competing route by methylating NAM to 1-MNA. Blocking NNMT can reduce the measured conversion of NAM to 1-MNA.
Whether this also produces a substantial increase in total or compartment-specific NAD+ depends on the rest of the NAD+ network, including precursor availability, NAMPT and NMNAT activity, redox metabolism, compartmentalization, PARP activity, sirtuin activity, CD38 activity, nutrient status, and cellular stress.
Reduced 1-MNA formation is therefore a more proximal functional marker of NNMT inhibition than a change in total-cell NAD+.
An increase in NAD+ should not automatically be described as proof of increased mitochondrial respiration, fatty-acid oxidation, SIRT1 activation, AMPK activation, or improved cellular function. Each downstream outcome requires direct measurement.
Correct interpretation of the differentiated-adipocyte NAD+ data
In differentiated 3T3-L1 adipocytes, the published experiment tested 5-Amino-1MQ concentrations from 0.3 to 60 µM for 24 hours. The authors reported an approximately 1.2- to 1.6-fold concentration-related NAD+ response across roughly 1 to 60 µM.[8]
The statistical result must be stated precisely. The overall one-way ANOVA did not reach the conventional P<0.05 threshold: F(5,6) = 4.131, P = 0.0568.
In the reported Dunnett post hoc analysis, the 10 µM group was significant versus control, whereas the experiment did not establish that every tested concentration produced a statistically significant NAD+ increase.[8]
The same experiment reported a significant overall treatment effect on intracellular SAM, with a significant increase at 30 µM and a borderline comparison at 60 µM, while no significant overall treatment effects were reported for NAM or SAH under those conditions.[8]
These metabolite measurements were conducted in biological duplicates. They support a model-specific metabolic response, but their small sample size limits precision and generalizability.
The results should not be automatically extended to primary human adipocytes, liver cells, skeletal-muscle cells, immune cells, other species, or whole-organism physiology.
The NNMT–SAM–SAH Axis
Each NNMT-catalyzed reaction consumes one molecule of SAM and produces one molecule of SAH. SAM is a methyl donor for DNA, RNA, protein, histone, phospholipid, and small-molecule methylation reactions.
SAH can inhibit multiple SAM-dependent methyltransferases when it accumulates, and the SAM:SAH ratio is often investigated as one indicator of cellular methylation potential.
NNMT activity can therefore be studied in relation to:
- intracellular SAM and SAH concentrations;
- the SAM:SAH ratio;
- specific histone methylation marks;
- DNA methylation at defined loci;
- expression of genes connected to directly measured chromatin changes.
Genetic NNMT knockdown in diet-induced obese mice reduced NNMT expression in white adipose tissue and liver. Changes in SAM-related metabolism, H3K4 methylation, polyamine-pathway gene expression, and energy-expenditure-related endpoints were demonstrated primarily in adipose tissue.[9]
These genetic findings support a relationship between NNMT activity and methyl-donor balance, but they are not direct proof that 5-Amino-1MQ produces the same locus-specific epigenetic changes. Genetic depletion and small-molecule inhibition are complementary but non-identical approaches.
Genetic manipulation may alter enzyme abundance, protein interactions, developmental timing, long-term adaptation, and compensatory transcription. A small-molecule inhibitor can instead produce concentration- and time-dependent inhibition while leaving the enzyme protein present.
Claims that 5-Amino-1MQ changes methylation at a particular promoter or enhancer require direct evidence, such as chromatin immunoprecipitation, targeted DNA methylation analysis, histone-mark immunoblotting, mass-spectrometric histone analysis, and matched gene-expression measurements. Without such experiments, the SAM–methylation relationship should be described as a plausible pathway rather than a proven locus-specific effect.
1-MNA is not necessarily an inert waste product
1-MNA is a direct product of NNMT and is commonly used as a proximal biochemical marker of NNMT activity. It should not, however, be described solely as an inactive disposal product.
In one study, cultured human myotubes secreted 1-MNA, and exogenous 1-MNA stimulated lipolysis in the tested experimental system.[10] Separate animal and vascular studies reported prostacyclin-associated antithrombotic or vascular effects under specific conditions.[11]
These findings do not establish 1-MNA as a universal signaling molecule or predict its effect in every tissue. They do show that a phenotype after NNMT inhibition may reflect several concurrent biochemical changes:
- reduced NAM methylation;
- reduced 1-MNA formation;
- altered NAM availability;
- altered NAD+ salvage;
- altered SAM consumption;
- altered SAH production;
- secondary metabolic adaptation.
A mechanistic study should distinguish among these possibilities instead of attributing every downstream observation to one metabolite or pathway.
Adipocyte Research Applications
Fully differentiated adipocytes: proximal NNMT engagement
In fully differentiated 3T3-L1 adipocytes, the most proximal functional endpoint reported for 5-Amino-1MQ is reduced intracellular 1-MNA formation after compound exposure.[8]
Additional research endpoints may include:
- NAM concentration;
- NAD+ and NADH;
- the NAD+:NADH ratio;
- SAM and SAH;
- the SAM:SAH ratio;
- triglyceride content;
- lipid-droplet staining;
- adipocyte gene expression;
- cell viability and cell number.
A change in lipid staining alone cannot establish the responsible mechanism. Reduced Oil Red O or BODIPY signal may result from impaired differentiation, reduced lipid synthesis, increased lipid mobilization, lower cell number, delayed growth, cytotoxicity, or differences in staining and normalization procedures.
Lipid-related experiments should therefore include matched viability, cell-number, DNA, or protein-normalization controls.
Differentiating pre-adipocytes: do not confuse differentiation with mature-cell treatment
The original 5-Amino-1MQ study included a separate experiment in which 3T3-L1 pre-adipocytes were exposed during the differentiation process and later evaluated for lipid accumulation. That design is not equivalent to treating fully differentiated adipocytes.[8]
Accordingly, the most accurate interpretation is:
- fully differentiated adipocytes were used to demonstrate intracellular NNMT-related metabolic effects, including reduced 1-MNA;
- pre-adipocytes treated during differentiation were used to assess later lipid accumulation and adipogenesis-related outcomes.
The effect of NNMT manipulation can depend strongly on treatment timing. Exposure during early commitment or mitotic clonal expansion is not equivalent to exposure after terminal differentiation.
A 2023 study using genetic NNMT knockout and a different NNMT inhibitor, CC-410, found that NNMT participates in the early glucocorticoid–CEBPB regulatory network of 3T3-L1 adipogenesis. NNMT loss altered mitotic clonal expansion and reduced terminal differentiation and late adipogenic markers, including Pparg, Cebpa, and Lpl.[12]
That study did not use 5-Amino-1MQ as its pharmacological inhibitor. It supports a broader role for NNMT in adipogenesis but is not direct evidence that 5-Amino-1MQ reproduces every CC-410 effect.
Adipocyte-differentiation studies should specify:
- cell line, source, and passage range;
- the differentiation protocol;
- the exact treatment window;
- whether treatment occurred before, during, or after induction;
- vehicle identity and final concentration;
- exposure duration;
- number of biological replicates;
- normalization method;
- viability and cytotoxicity results.
Gene-expression endpoints
Common adipocyte markers include PPARG, CEBPA, CEBPB, FABP4, ADIPOQ, PLIN1, FASN, ACACA, SCD1, LPL, NAMPT, and NNMT.
Changes in these markers must be interpreted according to the stage of differentiation. Lower PPARG or CEBPA during differentiation may indicate impaired terminal adipogenesis, whereas the same observation in mature adipocytes may reflect a different biological response.
Gene-expression changes do not prove altered enzyme activity unless the corresponding protein, metabolite, or functional endpoint is also measured.
Cellular Energy-Metabolism Endpoints
Because NNMT intersects with NAM, NAD+, SAM, SAH, and 1-MNA, researchers may investigate downstream cellular energy metabolism. Potential endpoints include oxygen-consumption rate, extracellular-acidification rate, basal and maximal respiration, spare respiratory capacity, ATP-linked respiration, cellular ATP, mitochondrial membrane potential, fatty-acid oxidation, AMPK phosphorylation, and sirtuin-associated deacetylation markers.
These are appropriate research endpoints, but they should not be presented as established effects of 5-Amino-1MQ unless the specific experiment directly measured them.
An increase in NAD+ alone does not demonstrate SIRT1 activation. AMPK phosphorylation is also not specific to NNMT inhibition and can change in response to nutrient depletion, mitochondrial stress, oxidative stress, altered ATP production, serum conditions, cell density, solvent exposure, or cytotoxicity.
Energy-metabolism studies should include vehicle controls, cell-number or protein normalization, viability measurements, time-course analysis, direct 1-MNA measurement, appropriate positive controls, and orthogonal NNMT validation where practical.
Evidence from Laboratory Animal Models
5-Amino-1MQ has been evaluated in diet-induced obesity mouse models. These studies are preclinical and should be interpreted only within their specific protocols.
Original high-fat-diet mouse experiments
The original preclinical study reported that NNMT inhibition was associated with reduced adipose-tissue 1-MNA, changes in metabolic measurements, and differences in body weight and adiposity-related endpoints in high-fat-diet mouse models.[8]
Combination with reduced-calorie diet
A later study examined 5-amino-1-methylquinolinium together with a reduced-calorie diet intervention in diet-induced obese mice. Relative to diet substitution alone, the combined protocol was associated with greater body-weight and fat-mass loss, changes in epididymal white adipose tissue and liver endpoints, improved steatosis-related measures, and a distinct adipose-tissue metabolomic profile.[13]
The result cannot be interpreted as a pure compound-only effect because the intervention combined pharmacological treatment with a diet change.
2024 obesity-related metabolic study
A 2024 study in diet-induced obese mice reported that 5A1MQ dose-dependently limited body-weight and fat-mass gain, improved oral glucose tolerance and insulin-sensitivity-related measures, suppressed hyperinsulinaemia, and attenuated hepatic steatosis, macrophage infiltration, liver triglyceride accumulation, and related liver endpoints. The study also included plasma pharmacokinetic and tissue-distribution analyses.[14]
These findings remain mouse data. They do not establish:
- human efficacy;
- human safety;
- a human dose;
- a veterinary dose;
- a suitable administration route outside an approved protocol;
- long-term safety in other species;
- suitability for personal use.
Animal-model results can depend on mouse strain, sex, age, diet composition, housing, treatment duration, vehicle, route, feeding behavior, baseline adiposity, sample size, randomization, blinding, and statistical design.
Every animal experiment must be conducted under an institutionally approved protocol and applicable animal-welfare requirements.
Direct, Proximal, and Downstream Endpoints
To avoid mechanistic overinterpretation, endpoints can be organized into three levels.
Direct or proximal NNMT-related endpoints
- purified-enzyme NNMT activity;
- 1-MNA formation;
- NAM consumption;
- direct binding, occupancy, or thermal-stabilization evidence where available.
Proximal metabolic endpoints
- NAD+ and NADH;
- NMN;
- SAM and SAH;
- the SAM:SAH ratio.
Downstream biological endpoints
- lipid accumulation;
- adipocyte differentiation;
- gene expression;
- histone or DNA methylation;
- mitochondrial respiration;
- ATP production;
- cell proliferation and viability;
- tissue-level metabolic phenotypes.
The farther an endpoint is from the NNMT reaction, the more alternative explanations must be considered. A strong mechanistic design links reduced 1-MNA or other target-proximal evidence to measured metabolite changes and then to a defined functional endpoint.
Without proximal target-engagement evidence, a change in lipid staining, respiration, or gene expression cannot confidently be assigned to NNMT inhibition.
Laboratory Handling and Solution-Preparation Principles
All information in this section concerns professional laboratory research preparation only. It is not a human or veterinary administration guide.
Solubility should not be inferred from the compound name alone. Research materials may differ in counterion, water content, crystal form, particle size, lot-specific purity, manufacturing history, and reported solvent compatibility.
A formulation used in one paper does not establish universal solubility or stability for every synthesized or commercial batch. Researchers should not assume that DMSO is always required, that water is always suitable, or that one solvent concentration is compatible with every cell model.
Before beginning an experiment, the laboratory should verify:
- the exact chemical and salt identity;
- the formula weight used in calculations;
- the COA and analytical status;
- the stated or experimentally confirmed solvent compatibility;
- the absence of visible precipitation at the required research concentration;
- solution stability during the intended experimental period;
- the final vehicle concentration;
- the tolerance of the exact biological system to that vehicle.
A universal rule such as “keep final DMSO below 0.1%” is not sufficient by itself. Although 0.1% DMSO is commonly used as an initial vehicle-control target in cell culture, some models respond to lower concentrations and others tolerate higher concentrations.
Acceptability must be tested in the exact model and exposure duration.
If the required concentration cannot be reached without precipitation or an unacceptable vehicle concentration, the study design should be revised rather than forcing the material into solution.
Molarity calculations
All molarity calculations must use the molecular weight of the actual supplied material:
Moles = mass ÷ molecular weight
Researchers should also account for any assay correction, water correction, or salt correction stated on the COA. A nominal HPLC area percentage should not automatically be used as an assay correction unless the COA or analytical method defines it as such.
No concentration used in a published cell or animal study should be converted into a personal-use or non-research amount.
Storage
Solid research material should be stored according to the batch-specific COA and supplier documentation. Some suppliers specify storage near −20°C in a tightly sealed, dry, light-protected container, but lot-specific documentation takes priority over a generic storage statement.
Prepared solutions should not be assumed to have the same stability as the solid material. Unless supported by validated stability data, laboratories should avoid unnecessary long-term solution storage, repeated freeze-thaw cycles, prolonged room-temperature exposure, uncontrolled light exposure, use after visible precipitation or color change, and any assumption of sterility based only on visual clarity.
Recommended Experimental Controls
Chemical and vehicle controls
- untreated control;
- vehicle-only control;
- matched vehicle concentration at every treatment level;
- positive assay control where available;
- precipitation and solution-clarity observations.
Biological controls
- cell-viability testing;
- cell counting;
- protein or DNA normalization;
- LDH-release or membrane-integrity testing where appropriate;
- microscopic evaluation;
- time-matched controls.
Target-validation controls
- measurement of 1-MNA;
- NNMT knockdown or knockout;
- NNMT overexpression;
- comparison with a structurally distinct NNMT inhibitor;
- binding or occupancy measurements where available;
- rescue or metabolite-addition experiments where scientifically justified.
Genetic and chemical approaches should be interpreted as complementary rather than identical. If the compound produces the same phenotype in NNMT-deficient cells as in control cells, possible explanations include an NNMT-independent effect, incomplete loss of NNMT function, altered metabolite transport, or another experimental variable requiring investigation.
Limits of the Current Evidence
This article is a narrative review of selected primary studies, not a systematic review or meta-analysis.
- Much of the adipocyte and obesity-related evidence comes from a limited number of overlapping investigator groups.
- Several key studies were produced by overlapping investigator groups. The 2024 study disclosed current or former author relationships with Ridgeline Therapeutics; this does not invalidate the data, but independent replication remains important.[14]
- Experimental concentrations and exposure periods vary between studies.
- Some influential cell experiments used biological duplicates or only two replicates per concentration point.
- Cellular potency is not identical to biochemical potency.
- Complete proteome-wide and systems-level off-target profiling has not been established.
- Total-cell NAD+ measurements do not resolve compartment-specific NAD+ pools.
- Genetic NNMT depletion and pharmacological inhibition may produce different adaptations.
- Some downstream mechanistic claims remain inferential rather than directly measured.
- Animal-model observations do not establish effects outside the tested model.
- The cited literature does not establish a non-research consumer application.
Researchers should avoid statements implying that NNMT inhibition automatically produces increased mitochondrial activity, specific promoter methylation changes, reduced adiposity, improved glucose metabolism, or another downstream phenotype in every model.
Accurate reporting should identify the experimental model, intervention, measured endpoint, direction of the observation, relevant statistical result, sample size, and limitations of causal interpretation.
Research Interpretation Summary
5-Amino-1MQ is best understood as a quinolinium small-molecule inhibitor used to investigate NNMT-dependent biochemical pathways.
The most proximal expected consequence of NNMT inhibition is reduced conversion of NAM and SAM into 1-MNA and SAH. Potential downstream changes in NAD+, SAM availability, methylation potential, adipocyte differentiation, lipid accumulation, mitochondrial metabolism, or gene expression are model-dependent and require direct measurement.
The strongest experimental designs combine:
- verified chemical identity and batch information;
- direct or proximal NNMT-engagement measurements;
- metabolite analysis;
- functional cellular endpoints;
- vehicle and viability controls;
- genetic or structurally independent validation;
- careful separation of mature-cell, differentiation-stage, and animal-model conclusions;
- transparent reporting of sample size and statistical limitations.
5-Amino-1MQ should not be described as a peptide, a universally selective compound, a proven locus-specific epigenetic modifier, an approved medicine, or a compound with established effects outside controlled laboratory research.
References
- PubChem. NNMTi / 5-amino-1-methylquinolinium iodide compound record.
https://pubchem.ncbi.nlm.nih.gov/compound/NNMTi - PubChem. 5-Amino-1-methylquinolinium compound record.
https://pubchem.ncbi.nlm.nih.gov/compound/5-Amino-1-methylquinolinium - U.S. FDA Global Substance Registration System. 5-Amino-1-methylquinolinium.
FDA GSRS record. - U.S. Food and Drug Administration. GenoGenix LLC Warning Letter, January 20, 2026.
FDA warning letter. - International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures, 2025 error-corrected version.
Official PDF. - International Council for Harmonisation. ICH Q3C(R8): Impurities—Guideline for Residual Solvents.
Official PDF. - Loring HS, Thompson PR. Kinetic Mechanism of Nicotinamide N-Methyltransferase.
Biochemistry. 2018;57(38):5524–5532.
doi:10.1021/acs.biochem.8b00775. - Neelakantan H, Vance V, Wetzel MD, Wang HYL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ.
Selective and membrane-permeable small-molecule inhibitors of nicotinamide N-methyltransferase reverse high-fat-diet-induced obesity in mice.
Biochemical Pharmacology. 2018;147:141–152.
PMCID: PMC5826726. - Kraus D, Yang Q, Kong D, et al.
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.
Nature. 2014;508:258–262.
doi:10.1038/nature13198. - Ström K, Morales-Alamo D, Ottosson F, et al.
N1-methylnicotinamide is a signalling molecule produced in skeletal muscle coordinating energy metabolism.
PMCID: PMC5813101. - Chlopicki S, Swies J, Mogielnicki A, et al.
1-Methylnicotinamide, a primary metabolite of nicotinamide, exerts antithrombotic activity mediated by the cyclooxygenase-2/prostacyclin pathway.
PMID: 17641676. - Nicotinamide N-methyltransferase regulates the glucocorticoid signaling pathway during the early phase of adipogenesis.
Scientific Reports. 2023.
Official article. - Sampson CM, Dimet-Wiley A, et al.
Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice.
Scientific Reports. 2021;11.
Official article. - Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H.
Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction.
Diabetes, Obesity and Metabolism. 2024;26(11):5272–5282.
PMCID: PMC11622326;
doi:10.1111/dom.15879.
Research Use Only Disclaimer
Research Use Only: The research-grade materials discussed in this article are intended exclusively for qualified laboratory research purposes and are not approved for human or veterinary use. This article provides informational context regarding selected preclinical literature and laboratory material-quality principles.
It does not constitute medical, clinical, veterinary, dosing, treatment, or self-experimentation guidance.